Skip to main content


Generic name: mosunetuzumab-axgb
Dosage form: injection, for intravenous infusion
Drug class: Miscellaneous antineoplastics

Medically reviewed by Judith Stewart, BPharm. Last updated on Jan 6, 2023.

What is Lunsumio?

Lunsumio is a prescription medicine used to treat adults with follicular lymphoma, a cancer of the lymphatic system in which B lymphocytes (B cells) become cancerous and accumulate in 'follicles' in the lymph nodes. It the most common slow-growing form of non-Hodgkin’s lymphoma.

Lunsumio contains mosunetuzumab, a first-in-class bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells. It works by activating and redirecting the T cells to engage and eliminate the target B cells.

What is Lunsumio used to treat?

Lunsumio is used to treat adults with follicular lymphoma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory), and who have already received two or more treatments for their cancer.

It is not known if this medicine is safe and effective in children.

Important information

Lunsumio may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment, and can also be severe or life-threatening. Get medical help right away if you develop any signs or symptoms of CRS at any time, including:

Due to the risk of CRS, you will receive Lunsumio on a "step-up dosing schedule".

Your healthcare provider will check you for CRS during treatment, and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment if you have severe side effects.

See Lunsumio side effects for more information about side effects.

Before receiving Lunsumio

Before you start treatment, tell your healthcare provider about all of your medical conditions, including if you:

What other drugs will affect Lunsumio?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive Lunsumio?

See Important information for more information about how you will receive Lunsumio.

Dosing information

Usual Adult Dose for Follicular Lymphoma 

A treatment cycle is 21 days. 

Day of Treatment Dose Rate of Infusion
Cycle 1 Day 1  1 mg Administer over a minimum of 4 hours.
Day 8  2 mg
Day 15  60 mg
Cycle 2 Day 1  60 mg Administer over 2 hours if infusions from Cycle 1 were well-tolerated.
Cycles 3+ Day 1  30 mg

Comment: Premedicate to reduce risk of cytokine release syndrome and infusion-related reactions. Administer only as an intravenous infusion. Administer for 8 cycles, unless patients experience unacceptable toxicity or disease progression. 

Use: treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

What should I avoid while receiving Lunsumio?

Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.

See Important information and Lunsumio side effects for more information about signs and symptoms of CRS and neurologic problems.

Lunsumio side effects

Lunsumio may cause serious side effects, including:

See Important information

Tell your healthcare provider if you develop any of these signs or symptoms of tumor flare during your treatment: tender or swollen lymph nodes, chest pain, cough, trouble breathing, and pain or swelling at the site of the tumor.

Your healthcare provider may temporarily stop or permanently stop treatment if you develop severe side effects.

The most common side effects of Lunsumio include tiredness, rash, fever, and headache.

The most common severe abnormal lab test results with Lunsumio include decreased phosphate, increased glucose, and increased uric acid levels.

These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of Lunsumio.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information that is written for health professionals.

What are the ingredients in Lunsumio?

Active ingredient: mosunetuzumab-axgb
Inactive ingredients: acetic acid, histidine, methionine, polysorbate 20, sucrose, and Water for Injection

Popular FAQ

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.